search
Back to results

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

Primary Purpose

Chronic Hypertension

Status
Terminated
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
TC-5214
TC-5214
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Chronic Hypertension focused on measuring Phase I, Randomised, Placebo-Controlled, Double-Blind,Hypertensive Patients, Blood Pressure, Calcium Channel Blockers, Beta Blockers, ACE Inhibitors, Scientific terminology: To determine if treatment with TC5214 alone or in combination with Anti-Hypertensive Medications has an effect on sitting blood pressure, Laymen terminology: Hypertension

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures
  • Male or female patients with chronic, stable hypertension treated for at least 1 month before screening with a calcium channel blocker, a beta blocker, or an ACE inhibitor, either as the only anti-hypertensive medication or concurrently with a diuretic. The patients should have no change in their current anti hypertensive treatment for at least 1 month before dosing
  • Patients in Part 1 should have an SBP of ≤140 mmHg at screening and ≤160 mmHg at Visit 1a and pre-dose on Day 1
  • Patients in Part 2 should have an SBP of ≤160 mmHg at screening Visit 1 and pre dose on Day 1. Systolic blood pressure and DBP should not vary by more than 8 mmHg and 5 mmHg, respectively, in the pre-dose period (screening, Visit 1a, and pre-dose on Day 1)
  • Age 18 to 65 years (inclusive)

Exclusion Criteria:

  • Other than having chronic hypertension, the history of any clinically significant medical, neurologic, or psychiatric disease or disorder which, in the opinion of the Investigator and/or the Sponsor, may either put the patient at risk because of participation in the study or influence the results, or the patient's ability to participate in the study. Patients with dyslipidaemia (diet controlled or treated with a statin) and/or metabolic syndrome (diet controlled or treated with metformin) may be entered into the study
  • Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the investigational product
  • Patients with a pre-treatment SBP (if known) of >180 mmHg or a history of accelerated or malignant hypertension based on grade III (hypertensive haemorrhages and/or cotton wool spots) or grade IV (hypertensive papilloedema) retinopathy at any time
  • History or presence of gastrointestinal (including irritable bowel disease), hepatic, or renal disease (creatinine clearance of ≤50 mL/minute calculated using the Cockcroft Gault equation) or any other condition known to interfere with the ADME of the investigational product.
  • Patients with a history of surgery on the gastrointestinal tract (not including appendectomy or cholecystectomy) should also be excluded
  • Any significant ECG abnormality including QTcF prolongation (>450 ms) or significant arrhythmias, or junctional rhythms

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

1

2

3

4

Arm Description

TC-5214

TC-5214 with placebo

TC-5214 with placebo

TC-5214

Outcomes

Primary Outcome Measures

Part 1: To measure the effect of TC-5214 on sitting blood pressure in patients with chronic hypertension.
The following assessments will be measured and reported: - A change from baseline in blood pressure and pulse rate.
Part 2: To measure the effect of TC-5214 combined with treatment with the common classes of anti-hypertensive medication (calcium channel blockers, beta blockers, angiotensin converting enzyme inhibitors) on sitting blood pressure.
The following assessments will be measured and reported: A change from baseline in blood pressure and pulse rate.

Secondary Outcome Measures

To examine the safety and tolerability of TC-5214.
The following assessments will be measured and reported: The number of particpants with adverse events A change from baseline in blood pressure and pulse rate A change from baseline in laboratory assessments A change from baseline in vital signs A change from baseline in electrocardiogram (ECG) A change from baseline in physical examination
The concentration of TC-5214 in plasma will be measured.

Full Information

First Posted
July 26, 2011
Last Updated
October 1, 2012
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT01403922
Brief Title
To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension
Official Title
A Phase I Randomised, Placebo-Controlled, Double-Blind Study in Hypertensive Patients of the Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2012
Overall Recruitment Status
Terminated
Why Stopped
Sponsor's decision to terminate
Study Start Date
August 2011 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
August 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

5. Study Description

Brief Summary
This is a two part study. Part 1 will determine determine if administration of TC-5214 has an effect on sitting blood pressure in patients with chronic hypertension. Part 2 will determine any possible interactions between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors).
Detailed Description
A Phase I Randomised, Placebo-Controlled, Double-Blind Study in Hypertensive Patients of the Blood Pressure Interaction between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Hypertension
Keywords
Phase I, Randomised, Placebo-Controlled, Double-Blind,Hypertensive Patients, Blood Pressure, Calcium Channel Blockers, Beta Blockers, ACE Inhibitors, Scientific terminology: To determine if treatment with TC5214 alone or in combination with Anti-Hypertensive Medications has an effect on sitting blood pressure, Laymen terminology: Hypertension

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
TC-5214
Arm Title
2
Arm Type
Experimental
Arm Description
TC-5214 with placebo
Arm Title
3
Arm Type
Experimental
Arm Description
TC-5214 with placebo
Arm Title
4
Arm Type
Experimental
Arm Description
TC-5214
Intervention Type
Drug
Intervention Name(s)
TC-5214
Intervention Description
Tablet oral bid days 1 to 7
Intervention Type
Drug
Intervention Name(s)
TC-5214
Intervention Description
Tablet oral bid days 8 to 14
Primary Outcome Measure Information:
Title
Part 1: To measure the effect of TC-5214 on sitting blood pressure in patients with chronic hypertension.
Description
The following assessments will be measured and reported: - A change from baseline in blood pressure and pulse rate.
Time Frame
Day 1 through to follow up
Title
Part 2: To measure the effect of TC-5214 combined with treatment with the common classes of anti-hypertensive medication (calcium channel blockers, beta blockers, angiotensin converting enzyme inhibitors) on sitting blood pressure.
Description
The following assessments will be measured and reported: A change from baseline in blood pressure and pulse rate.
Time Frame
Day 1 through to follow up
Secondary Outcome Measure Information:
Title
To examine the safety and tolerability of TC-5214.
Description
The following assessments will be measured and reported: The number of particpants with adverse events A change from baseline in blood pressure and pulse rate A change from baseline in laboratory assessments A change from baseline in vital signs A change from baseline in electrocardiogram (ECG) A change from baseline in physical examination
Time Frame
Day 1 through to Follow up
Title
The concentration of TC-5214 in plasma will be measured.
Time Frame
Day 1 to day 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provision of informed consent prior to any study specific procedures Male or female patients with chronic, stable hypertension treated for at least 1 month before screening with a calcium channel blocker, a beta blocker, or an ACE inhibitor, either as the only anti-hypertensive medication or concurrently with a diuretic. The patients should have no change in their current anti hypertensive treatment for at least 1 month before dosing Patients in Part 1 should have an SBP of ≤140 mmHg at screening and ≤160 mmHg at Visit 1a and pre-dose on Day 1 Patients in Part 2 should have an SBP of ≤160 mmHg at screening Visit 1 and pre dose on Day 1. Systolic blood pressure and DBP should not vary by more than 8 mmHg and 5 mmHg, respectively, in the pre-dose period (screening, Visit 1a, and pre-dose on Day 1) Age 18 to 65 years (inclusive) Exclusion Criteria: Other than having chronic hypertension, the history of any clinically significant medical, neurologic, or psychiatric disease or disorder which, in the opinion of the Investigator and/or the Sponsor, may either put the patient at risk because of participation in the study or influence the results, or the patient's ability to participate in the study. Patients with dyslipidaemia (diet controlled or treated with a statin) and/or metabolic syndrome (diet controlled or treated with metformin) may be entered into the study Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the investigational product Patients with a pre-treatment SBP (if known) of >180 mmHg or a history of accelerated or malignant hypertension based on grade III (hypertensive haemorrhages and/or cotton wool spots) or grade IV (hypertensive papilloedema) retinopathy at any time History or presence of gastrointestinal (including irritable bowel disease), hepatic, or renal disease (creatinine clearance of ≤50 mL/minute calculated using the Cockcroft Gault equation) or any other condition known to interfere with the ADME of the investigational product. Patients with a history of surgery on the gastrointestinal tract (not including appendectomy or cholecystectomy) should also be excluded Any significant ECG abnormality including QTcF prolongation (>450 ms) or significant arrhythmias, or junctional rhythms
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hans A Eriksson, MD, PhD, MBA
Organizational Affiliation
AstraZeneca PharmaceuticalsKvarnbergagatan 12, 15185, Sodertalje, Sweden
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
James Ritter, MD,FRCP FFPM
Organizational Affiliation
Quintiles Drug Research Unit at Guy's HospitalQuintiles Limited6 Newcomen StreetLondon SE1 1YR
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
Overland Park
State/Province
Kansas
Country
United States
Facility Name
Research Site
City
Willingboro
State/Province
New Jersey
Country
United States
Facility Name
Research Site
City
Berlin
Country
Germany
Facility Name
Research Site
City
London
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

We'll reach out to this number within 24 hrs